沉默NOTCHI基因对多发性骨髓瘤RPMI 8226细胞生物学的影响

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (9): 978-983.

沉默NOTCHI基因对多发性骨髓瘤RPMI 8226细胞生物学的影响

黄晓璐¹，马旭东¹，鹿全意²

¹福建医科大学附属漳州市医院血液科，漳州 363000，福建；²厦门大学附属中山院血液科，厦门 361004，福建

收稿日期:2017-04-14 修回日期:2017-09-05 出版日期:2017-09-26 发布日期:2017-09-30
通讯作者: 马旭东，女，硕士研究生，主任医师，教授，研究方向：血液学。 E-mail：1072613096@qq.com 鹿全意，男，博士，主任医师，副教授，研究方向：血液学。 E-mail：njjinyue@126.com
作者简介:黄晓璐，女，硕士研究生，医师，研究方向：内科血液学肿瘤。
基金资助:
国家自然科学基金项目（81172246）

Effects of silencing NOTCH1 gene by eukaryotic vector in multiple myeloma RPMI 8226 cell line

HUANG Xiaolu ¹, MA Xudong ¹, LU Quanyi ²

¹Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian, China; ² Department of Hematology, Zhongshan Affiliated Hospital of Xiamen University, Xiamen 361000, Fujian, China

Received:2017-04-14 Revised:2017-09-05 Online:2017-09-26 Published:2017-09-30

摘要/Abstract

摘要：

目的: 探讨沉默NOTCH1基因对多发性骨髓瘤细胞株RPMI 8226增殖和凋亡的影响。方法: 针对人NOTCH1基因序列构建NOTCH1 shRNA真核表达载体，用Lipofectamine^TM2000脂质体转染RPMI 8226细胞，筛选出最佳干扰表达载体。观察NOTCH1 shRNA表达载体对RPMI 8226细胞增殖的影响；使用流式细胞仪分析细胞的周期分布；Western blot 法检测NOTCH1 shRNA转染RPMI 8226细胞后NOTCH1蛋白及细胞周期蛋白依赖性激酶抑制蛋白P27、P21的表达含量变化，ELISA法检测NOTCH1 shRNA转染RPMI 8226细胞后对IL-6分泌量的影响。结果: 沉默NOTCH1基因抑制细胞增殖，阻滞RPMI 8226细胞于G0/G1期，转染组、阴性对照组及空白组增殖率分别为（49.09±2.31）%、（91.73±2.67）%、（98.10±0.41）%，差异具有统计学意义（P<0.05）；三组的G0/G1期细胞分别为（66.23±3.71）%、（42.27±3.65）%、（40.70±0.92）%（P<0.05）；三组S期细胞分别为（31.03±1.49）%、（56.53±1.76）%、（51.83±1.45）%（P<0.05）。NOTCH1 shRNA诱导细胞凋亡，三组凋亡率分别为（46.67±1.31）%、（1.37±0.63）%、（0.85±0.43）%（P<0.05）；转染组NOTCH1蛋白表达下调，P21、P27表达上调。NOTCH1 shRNA可下调与疾病相关的IL-6分泌能力。三组IL-6分泌的吸光度值分别为28.18±3.50、167.08±7.97及185.86±5.61（P<0.05）。结论: NOTCH1 shRNA能抑制RPMI 8226细胞增殖并诱导凋亡，下调与多发性骨髓瘤发病有关的IL-6，有望成为多发性骨髓瘤治疗的一个新靶点。

关键词: NOTCH1, RNA干扰, 多发性骨髓瘤, RPMI 8226细胞

Abstract:

AIM: To discuss the impact of NOTCH1 shRNA on cell proliferation and apoptosis in multiple myeloma RPMI 8226 cell line. METHODS: Eukaryotic expression vector for human NOTCH1 gene (NOTCH1 shRNA) was synthesized, and eukaryotic expression vector was transfected into RPMI 8226 cells by LipofectamineTM2000. The influence of cell growth by NOTCH1 shRNA was determined by MTT. Cell apoptosis and cell-cycle distribution were measured by Flow cytometry. Western blot was used for the detection of NOTCH1, P21 and P27. ELISA was used for detecting IL-6 secretion affected by NOTCH1 shRNA.RESULTS:NOTCH1 shRNA inhibited cell growth through blocking cell cycle in G0/G1 phase. The NOTCH1 shRNA group's cell growth rate was (49.09±2.31)%, Neg-shRNA group was (91.73±2.67)%, and blank group was (98.10±0.41)%, (P<0.05). The cell phase in G0/G1 with NOTCH1 shRNA group, Neg-shRNA group and blank group was (66.23±3.71)%, (42.27±3.65)%, (40.70±0.92)% respectively (P<0.05). The S phase was (31.03±1.49)%, (56.53±1.76)%, (51.83±1.45)% , respectively (P<0.05). NOTCH1 shRNA induces cell apoptosis in RPMI 8226 cells. The cell apoptotic rate was (46.67±1.31)% in NOTCH1 shRNA group, (1.37±0.63)% in Neg-shRNA group and (0.85±0.43)% in Blank group (P<0.05), respectively. The NOTCH1 protein was reduced and the expression of P27 and P21 protein were increased by transfected NOTCH1 shRNA. NOTCH1 shRNA downregulated IL-6 secretion. OD value of IL-6 secretion was 28.18±3.50, 167.08±7.97 and 185.86±5.61, respectively through three groups (P<0.05). CONCLUSION: NOTCH1 shRNA inhibits cell growth and induces cell apoptosis RPMI 8226 cell line, which may be a new treatment target in multiple myeloma.

Key words: NOTCH1, RNA interference, multiple myeloma, RPMI 8226 cell

中图分类号:

R965.2

黄晓璐，马旭东，鹿全意. 沉默NOTCHI基因对多发性骨髓瘤RPMI 8226细胞生物学的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 978-983.

HUANG Xiaolu, MA Xudong, LU Quanyi. Effects of silencing NOTCH1 gene by eukaryotic vector in multiple myeloma RPMI 8226 cell line[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 978-983.

参考文献

［1］LI Chun-Pu, WANG Jing, LIU Yan,et al.Inhibition of RPMI 8226 myeloma cell xenografted tumor angiogenesis by down regulation of Notch1［J］.J Int Oncol,2015,661.
［2］Galletti S, Colombo M, Ravaioli S, et al. Notch pathway and Inteleukin-6 cooperate to support multiple myeloma cell proliferation［J］. Clin Lymphoma Myeloma Leuk, 2015, 15:e233-e234.
［3］Garavelli S, Colombo M, Thümmler K, et al.Notch signaling dysregulation promotes multiple myeloma-associated bone disease［J］. Clin Lymphoma Myeloma Leuk, 2015, 15:e233-e233.
［4］Saltarella I, Lamanuzzi A, Leone P, et al. Involvement of NOTCH signaling in multiple myeloma angiogenesis and progression［J］. Clin Lymphoma Myeloma Leuk, 2015,15:e239-e240.
［5］Berenstein R, Nogai A, Waechter M, et al. Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223［J］. Mol Carcinog，2015, 55(12): 1927-1939.
［6］Ding Y, Shen Y. Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis［J］. Biochem Biophys Res Commun, 2015, 467(4):717-722.
［7］徐又海, 汪兴洪. Shh、Gli1基因在多发性骨髓瘤中的表达及临床意义［J］.中国临床药理学与治疗学, 2015, 20(3):309-313.
［8］Das DS, Das A, Ray A, et al. Blockade of deubiquitylating enzyme USP1 Inhibits DNA repair and triggers apoptosis in multiple myeloma cells ［J］. Clin Cancer Res, 2017，23(15):4280-4289.
［9］Colombo M, Galletti S, Bulfamante G, et al.Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche［J］. Oncotarget,2016, 7(35):56013-56029.
［10］Franquimachin R, Wendlandt EB, Janz S, et al. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction ［J］ ? Oncotarget, 2015, 6(38):40496-40506.
［11］Pisklakova A, Grigson E, Ozerova M, et al. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment［J］. Cancer Biol Ther, 2016, 17(5): 477-485.
［12］宋今丹,章静波,陈誉华.医学细胞分子生物学［M］.北京:人民卫生出版社,2003:454.
［13］Gomes CC,Drummond SN,Guimaraes AL,et al.P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma［J］.J Oral Pathol Med，2008,37(3):151-156.
［14］郭益群, 陈世伦.多发性骨髓瘤骨髓基质细胞分泌IGF-1、VEGF和IL-6的动态变化［J］. 中华血液学, 2006, 27(4): 231-234.
［15］Acaz-Fonseca E, Sanchez-Gonzalez R, Astiz M, et al. Notch signaling is regulated by IGF-1 in astrocytes［C］// Biennial Meeting of the International-Society-For-Neurochemistry. 2015:102-102.
［16］赖静兰,刘玉明, 林春,等. 乙型肝炎相关慢加急性肝衰竭患者血清白细胞介素1受体拮抗剂与疾病严重程度的关系［J］.临床肝胆病杂志, 2016, 32(5):890-893.

[1]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.
[2]	段圆圆, 李子坚. Ciltacabtagene autoleucel——治疗复发难治性多发性骨髓瘤的靶向BCMA CAR-T细胞新型疗法[J]. 中国临床药理学与治疗学, 2022, 27(10): 1145-1154.
[3]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[4]	赵玮, 吴悠扬, 林丛, 黄时伟, 陈皓, 姜文兵. 紫檀芪对急性心肌梗死大鼠心肌功能、心肌纤维化和炎症反应的作用及对Notch1/eIF3a信号通路的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 498-504.
[5]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[6]	朱林佳，原少斐，上官宗校，慈晓，赵仁国，李玉苹. 超声-微泡介导的microRNA-449a通过调节Notch1对肺癌细胞的生长抑制作用[J]. 中国临床药理学与治疗学, 2019, 24(12): 1385-1393.
[7]	吴海兵，张刚，韩彬，郭晓珺，吉兆宁. 多发性骨髓瘤患者住院化疗感染的临床特征及影响因素研究[J]. 中国临床药理学与治疗学, 2018, 23(1): 93-98.
[8]	沈健，林颖超，朱夏吟. 小分子干扰RNA抑制HLX1表达对急性髓系白血病细胞侵袭的影响及机制探讨[J]. 中国临床药理学与治疗学, 2017, 22(6): 627-632.
[9]	茆家定，胡迪，吴佩. 胃泌素调控ERK信号通路在促进大肠癌CACO2细胞增殖中的作用[J]. 中国临床药理学与治疗学, 2017, 22(4): 401-405.
[10]	徐又海, 汪兴洪. Shh、Gli1基因在多发性骨髓瘤中的表达及临床意义[J]. 中国临床药理学与治疗学, 2015, 20(3): 309-313.
[11]	罗慧英, 杨林, 王晓鹏, 苏河, 刘英, 马云涛, 吴自燕. siRNA沉默胃癌SGC-7901细胞COX-2基因对VEGF-C表达与细胞迁移的影响[J]. 中国临床药理学与治疗学, 2014, 19(9): 961-966.
[12]	洪娟, 汪兴洪. 多发性骨髓瘤骨病发病机制的研究及治疗进展[J]. 中国临床药理学与治疗学, 2013, 18(6): 705-709.
[13]	吕颖慧, 龚玉华, 刁勇, 许瑞安, 王启钊. 高迁移率族蛋白A2在肿瘤发生和血管形成中的双重作用[J]. 中国临床药理学与治疗学, 2011, 16(9): 975-980.
[14]	刘雪妮, 裴金仙, 李小亮, 臧国庆, 余永胜. 阻断Notch1信号通路对慢性乙肝患者外周血T细胞免疫功能的影响[J]. 中国临床药理学与治疗学, 2011, 16(2): 174-179.
[15]	黄来全, 韦中玲, 张军, 张岱云, 汪兴洪. BAG-1 及NF-κB P65 在多发性骨髓瘤患者骨髓单个核细胞中的表达[J]. 中国临床药理学与治疗学, 2010, 15(3): 292-297.